Next Generation of Immune Checkpoint Inhibitors
演讲题目:Next Generation of Immune Checkpoint Inhibitors
个人简介：Dr. Wenzhi Tian, 1000-Talent of Shanghai, is the founder and Chairman of ImmuneOnco Biopharma Co., Ltd, a start-up company in China, with primary focus of its R&D on tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANK) products that will meet the unmet medical needs both in China and global market.
Dr. Tian recently founded ImmuneOnco Biopharma in Zhangjiang Hi-Tech Park dedicating to Research and Development of tumor immunotherapeutic drugs. Dr. Tian returned back to China in April of 2011 from ImClone Systems and established Huabo Biopharm Co., Ltd where he worked as Chief Executive Officer until April of 2015. Dr. Tian joined ImClone Systems as a Research Scientist in January of 2006 and resigned at the position of Principal Research Scientist in April of 2011. Prior to joining ImClone Systems, He was CSO of Aoko Biotechnology Ltd. from July of 2005 to December of 2005, where he was dedicated to developing therapeutic vaccine against HIV using yeast technology platform. Prior to joining Aoko Biotechnology, he was a Senior Research Associate from April of 2001 to Jun of 2005 at the division of immunology, department of medicine, Weill Medical College of Cornell University, with main focus on cloning and characterizing novel genes from B lymphocytes. From October of 1997 to April of 2001, he was a postdoctoral fellow at the division of molecular immunology, department of Rheumatology and Allergy & Immunology, North Shore University Hospital, NYU School of Medicine, dedicated to cloning and characterizing genes involved in Ig class switch recombination. Dr. Tian got his M.D. at Henan Medical University in 1987 and trained as a Ph.D. candidate from 1995 to 1997 at the department of Neurology and Clinical Immunology, Karolinska Institute, Huddinge Unversity Hospital, Huddinge, Sweden.